Session » Antiphospholipid Syndrome: Clinical

Abstract Number: 2182

Increased Risk of Livedo Reticularis Associated with Antiphospholipid Antibodies in Patients with Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis

Abstract Number: 2183

Clinical and Epidemiological Correlates of the Adjusted Global Anti-Phospholipid Syndrome Score in a Large Cohort of Chinese APS Patients

Abstract Number: 2184

Non-Criteria Clinical Manifestations in Antiphospholipid Syndrome: Clinical Behavior and Association with Damage Accrual

Abstract Number: 2185

Small but Clinically Insignificant Decreases in Antiphospholipid Antibody Titers Occur in aPL-Positive Patients during Pregnancy

Abstract Number: 2186

The Role of Hydroxychloroquine Treatment on Pregnancy Outcome in Women with Antiphospholipid Antibodies

Abstract Number: 2187

Anti-Phosholipid Antibodies and Female Infertility: A Systematic Revision of Literature

Abstract Number: 2188

Antiphospholipid Antibodies and the Risk of Damage Accrual in Systemic Lupus Erythematosus

Abstract Number: 2189

Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking Clinical Database and Repository (“Registry”) Prospective Follow-up Analysis: One-Year First and Recurrent Thrombosis Risk

Abstract Number: 2190

Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Core Laboratory Validation Exercise: Comparison of Enzyme-Linked Immunosorbant Assay (ELISA) and Chemiluminescence Immunoassay (CIA)

Abstract Number: 2191

Increased Risk of Acute and Chronic Renal Lesions Associated with Antiphospholipid Antibodies in Patients with Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis

Abstract Number: 2192

Increased Risk of Thrombocytopenia Associated with Antiphospholipid Antibodies in Patients with Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis

Abstract Number: 2193

Increased Risk of Hemolytic Anemia Associated with Antiphospholipid Antibodies in Patients with Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis

Abstract Number: 2194

Anticoagulation and Longterm Outcomes in Patients with Renal Artery Stenosis and Antiphospholipid Syndrome

Abstract Number: 2195

Long Term Outcome of Primary Antiphospholipid Syndrome Patients: A Multicenter Study

Abstract Number: 2196

Association Between Antiphospholipid Antibodies and All-Cause Mortality Among End Stage Renal Disease Patients with and without SLE

Abstract Number: 2197

Risk Factors for Adverse Pregnancy Outcome in First-Line Treated Pregnancies in Antiphospholip Antibodies-Positive Women According to Different Treatment Protocols: A Single Center Experience over 30 Years

Abstract Number: 2198

Antiphospholipid Syndrome Alliance for Clinical Trials & International Networking Clinical Database and Repository Analysis: Determinants of Thrombosis in Patients Presenting with Obstetric APS

Abstract Number: 2199

in Vivo Ubiquinol Supplementation Reduces the Pro-Atherothrombotic Status in Antiphospholipid Syndrome Patients. Preliminary Results of a Clinical Trial

Abstract Number: 2200

Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking Clinical Database and Repository Cluster Analysis: Identification of Different Clinical Phenotypes Among Antiphospholipid Antibody-Positive Female Patients

Abstract Number: 2201

Triple Positivity of Antiphospholipid Antibody As the Main Thrombotic Factor in a Long-Term Follow-up Study of 98 Asymptomatic Apl-Positive Carriers

Abstract Number: 2202

Different Patterns of Positivity for IgG Anti-Cardiolipin, Anti-Beta-2-Glycoprotein I and Anti-Domain I Antibodies within the First Year of Disease in 501 Patients with SLE  – Associations  with Different Clinical Outcomes